Cluster Headache Increases Use of Sickness Absence and Disability Pension Days
Researchers aimed to determine whether patients with cluster headache have more sickness absence and disability pension days compared to matched references.
Researchers aimed to determine whether patients with cluster headache have more sickness absence and disability pension days compared to matched references.
A meta-analysis of 2 double-blind, sham-controlled trials found that noninvasive vagus nerve stimulation was effective for the acute treatment of episodic, but not chronic, cluster headache.
Researchers pooled data from 2 randomized, double-blind, placebo-controlled trials and found that noninvasive VNS is effective in aborting attacks in episodic cluster headache.
The supplemental New Drug Application (sNDA) for Emgality (galcanezumab-gnlm; Lilly) has been granted Priority Review by the Food and Drug Administration (FDA) for the preventive treatment of episodic cluster headache in adults.
SPG stimulation is delivered on-demand through an implanted neurostimulator.
The therapy effects lasted for about a month, as researchers noted the procedure would need to be repeated for continuous relief.
The noninvasive device not only stopped acute attacks, but reduced overall headache frequency.